Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DAROLUTAMIDE Cause Product dose omission issue? 85 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 85 reports of Product dose omission issue have been filed in association with DAROLUTAMIDE (NUBEQA). This represents 2.6% of all adverse event reports for DAROLUTAMIDE.

85
Reports of Product dose omission issue with DAROLUTAMIDE
2.6%
of all DAROLUTAMIDE reports
2
Deaths
25
Hospitalizations

How Dangerous Is Product dose omission issue From DAROLUTAMIDE?

Of the 85 reports, 2 (2.4%) resulted in death, 25 (29.4%) required hospitalization, and 1 (1.2%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DAROLUTAMIDE. However, 85 reports have been filed with the FAERS database.

What Other Side Effects Does DAROLUTAMIDE Cause?

Fatigue (384) Death (361) Hot flush (203) Asthenia (173) Prostatic specific antigen increased (156) Off label use (133) Neuropathy peripheral (127) Diarrhoea (122) Dizziness (122) Rash (116)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which DAROLUTAMIDE Alternatives Have Lower Product dose omission issue Risk?

DAROLUTAMIDE vs DARUNAVIR DAROLUTAMIDE vs DARUNAVIR ETHANOLATE DAROLUTAMIDE vs DARUNAVIR\RITONAVIR DAROLUTAMIDE vs DASABUVIR DAROLUTAMIDE vs DASABUVIR\OMBITASVIR HEMINONAHYDRATE\PARITAPREVIR\RITONAVIR

Related Pages

DAROLUTAMIDE Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue DAROLUTAMIDE Demographics